文献速递分子诊断临床微生物

Cobas CT/NG检测在Cobas 6800/8800系统上用于男女泌尿生殖道样本的性能评估

Evaluation of the Performance of the Cobas CT/NG Test for Use on the Cobas 6800/8800 Systems for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Male and Female Urogenital Samples.
PubMed 文献 · J Clin Microbiol · 2019-03-28

该多中心前瞻性收集研究评估了Cobas CT/NG检测在Cobas 6800/8800系统上检测男女泌尿生殖道样本中沙眼衣原体和淋病奈瑟菌的临床性能,以FDA批准的核酸扩增检测组合确定的患者感染状态为参考。结果显示女性尿液、阴道拭子(医生或自采)、宫颈拭子及PreservCyt宫颈样本的敏感性范围为92.5%-99.2%(衣原体)和94.8%-100.0%(淋球菌),特异性均≥98.8%和>99.0%;男性尿液敏感性均为100%,特异性分别为99.7%和99.5%。全自动检测有助于满足公共卫生控制需求。

要点

  • 女性阴道拭子(医生或自采)检测衣原体敏感性最高(98.6%-99.2%),宫颈PreservCyt样本最低(92.5%)。
  • 男性尿液检测衣原体和淋球菌敏感性均为100%,特异性分别为99.7%和99.5%。
  • 所有女性样本类型检测衣原体特异性≥98.8%,检测淋球菌特异性>99.0%。

核心结论

  • Cobas CT/NG检测在Cobas 6800/8800系统上对男女泌尿生殖道样本检测沙眼衣原体和淋病奈瑟菌具有高敏感性和特异性。

研究设计与样本

  • 多中心前瞻性收集研究,纳入男女泌尿生殖道样本,并补充存档标本数据,以FDA批准的核酸扩增检测组合确定的患者感染状态为参考标准。

主要发现

  • 女性尿液、医生采集阴道拭子、自采阴道拭子、宫颈拭子及PreservCyt宫颈样本检测沙眼衣原体敏感性分别为95.6%、98.6%、99.2%、93.3%、92.5%。
  • 女性上述样本检测沙眼衣原体特异性均≥98.8%。
  • 男性尿液检测沙眼衣原体敏感性和特异性分别为100%和99.7%。
  • 女性尿液、医生采集阴道拭子、自采阴道拭子、宫颈拭子及PreservCyt宫颈样本检测淋病奈瑟菌敏感性分别为94.8%、100.0%、100.0%、97.0%、96.6%。
  • 女性所有样本检测淋病奈瑟菌特异性>99.0%;男性尿液检测淋病奈瑟菌敏感性和特异性分别为100.0%和99.5%。

关键数值与推荐

  • 女性尿液检测沙眼衣原体敏感性95.6%(95%CI 92.4%-97.4%),特异性≥98.8%。
  • 女性医生采集和自采阴道拭子检测沙眼衣原体敏感性分别为98.6%(95%CI 95.2%-99.6%)和99.2%(95%CI 95.4%-99.9%)。
  • 女性宫颈拭子和PreservCyt宫颈样本检测沙眼衣原体敏感性分别为93.3%(95%CI 89.6%-95.7%)和92.5%(95%CI 88.7%-95.1%)。
  • 男性尿液检测沙眼衣原体敏感性100%(95%CI 96.8%-100.0%),特异性99.7%(95%CI 99.2%-99.9%)。
  • 女性尿液检测淋病奈瑟菌敏感性94.8%(95%CI 89.6%-97.4%),医生采集和自采阴道拭子均为100.0%(95%CI 87.9%-100.0%)。

临床怎么用

  • Cobas CT/NG检测可用于男女泌尿生殖道样本(尿液、阴道拭子、宫颈拭子等)的沙眼衣原体和淋病奈瑟菌筛查。
  • 全自动高通量检测有助于公共卫生控制沙眼衣原体和淋病奈瑟菌感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical performance of the Cobas CT/NG assay on the Cobas 6800/8800 systems (Cobas) for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae was established in a multisite, prospective collection study using male and female urogenital specimens; supportive data from archived specimens were also included. The results obtained with the Cobas assay were compared with the patient infected status derived from a combination of U.S. Food and Drug Administration-approved nucleic acid amplification tests to determine the sensitivity and specificity of detection from each sample type. The sensitivity of Cobas for the detection of C. trachomatis in female specimens was 95.6% (95% confidence interval [CI], 92.4% to 97.4%) for urine; 98.6% (95% CI, 95.2% to 99.6%) and 99.2% (95% CI, 95.4% to 99.9%) for clinician- and self-collected vaginal swab specimens, respectively; 93.3% (95% CI, 89.6% to 95.7%) for endocervical swabs; and 92.5% (95% CI, 88.7% to 95.1%) for cervical swab samples in PreservCyt. The specificity for the detection of C. trachomatis was ≥98.8% for all female sample types. Sensitivity and specificity estimates of Cobas for the detection of C. trachomatis in male urine samples were 100% (96.8% to 100.0%) and 99.7% (95% CI, 99.2% to 99.9%), respectively. The sensitivity of Cobas for the detection of N. gonorrhoeae in female specimens was 94.8% (95% CI, 89.6% to 97.4%) for urine; 100.0% (95% CI, 87.9% to 100.0%) and 100.0% (95% CI, 87.9% to 100.0%) for clinician- and self-collected vaginal swab specimens, respectively; 97.0% (95% CI, 91.5% to 99.0%) for endocervical swabs; and 96.6% (95% CI, 90.6% to 98.8%) for cervical samples in PreservCyt; the specificity for all female sample types was >99.0%. The sensitivity and specificity of Cobas for detecting N. gonorrhoeae in male urine were 100.0% (95% CI, 95.8% to 100.0%) and 99.5% (95% CI, 98.8% to 99.8%), respectively. Fully automated assays help fill the clinical need for a sensitive, high-throughput screening tool to aid public health efforts to control C. trachomatis and N. gonorrhoeae infections.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Van Der Pol B, Fife K, Taylor SN, et al. Evaluation of the Performance of the Cobas CT/NG Test for Use on the Cobas 6800/8800 Systems for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Male and Female Urogenital Samples. J Clin Microbiol. 2019. PMID: 30651389. doi:10.1128/JCM.01996-18

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。